Selenium functionalized intraocular lenses inhibit posterior capsule opacification in an ex vivo canine lens capsular bag assay.
The purpose of this study was to determine the inhibitory effect of selenocystamine coated intraocular lenses (IOLs) on the formation of posterior capsule opacification (PCO) in an ex vivo canine lens capsular bag assay. Selenocystamine was covalently bound to the surface of poly(2-hydroxyethyl methacrylate) (poly(HEMA)) discs. Three groups of canine lens capsules (6 coated IOLs (SeIOLs), 7 non-coated control IOLs and 8 empty capsules) were cultured for 10 days. During the culture period PCO was scored based on visual inspection of the capsules using phase contrast microscopy. On day 10 all the capsules were prepared for light microscopic examination and lens epithelial cells (LECs) were quantified. Proliferating cell nuclear antigen (PCNA), alpha-smooth muscle actin (alpha-SMA) and cleaved caspase-3 were examined by immunohistochemistry. Additionally, cell viability assays were performed on LECs cultured in tissue culture medium pre-incubated with either a SeIOL or control IOL. The viability assays demonstrated that no detectable cytotoxic leachables were associated with the functionalized IOLs. The central posterior capsule was free of cells underneath all SeIOLs, although large numbers of LECs populated the capsular periphery. Apoptotic cells were observed underneath the periphery of some SeIOLs. Both the PCO scores and LEC counts of SeIOL containing capsules were significantly lower than those of control group capsules (p < 0.01 and p = 0.0004, respectively). The use of selenium functionalized IOLs resulted in a significant reduction of PCO in this ex vivo model. Binding of selenocystamine to a foldable IOL may provide an effective method to prevent population of the central posterior capsule with LECs.
Pot
Simon A
SA
Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive, Madison, WI 53706, USA. sapotster@gmail.com
Chandler
Heather L
HL
Colitz
Carmen M H
CM
Bentley
Ellison
E
Dubielzig
Richard R
RR
Mosley
Thomas S
TS
Reid
Ted W
TW
Murphy
Christopher J
CJ
D000199:Actins / Q000378:metabolism; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D002386:Cataract / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D020099:Coated Materials, Biocompatible; D003538:Cystamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D004847:Epithelial Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007150:Immunohistochemistry; D007903:Lens Capsule, Crystalline / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007910:Lenses, Intraocular; D009924:Organ Culture Techniques; D016566:Organoselenium Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D011102:Polyhydroxyethyl Methacrylate / Q000737:chemistry*; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D013997:Time Factors
D000199:Actins; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D016566:Organoselenium Compounds; D018809:Proliferating Cell Nuclear Antigen; D011102:Polyhydroxyethyl Methacrylate; C014807:selenocystamine; D053148:Caspase 3; D003538:Cystamine